Effect of pramlintide on satiety and food intake in obese subjects and subjects with type 2 diabetes

The three-factor eating questionnaire to measure dietary restraint, disinhibition and hunger

Stunkard, A. J., & Messick, S. (1985) · Journal of Psychosomatic Research · doi:10.1016/0022-3999(85)90010-8 · Cited by 4,687 · see citing works

Ghrelin enhances appetite and increases food intake in humans

Wren, A. M., Seal, L. J., Cohen, M. A., Brynes, A. E., Frost, G. S., Murphy, K. G., Dhillo, W. S., Ghatei, M. A., & Bloom, S. R. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.12.8111 · Cited by 2,494 · see citing works

Gut hormone PYY3-36 physiologically inhibits food intake

Batterham, R. L., Cowley, M. A., Small, C. J., Herzog, H., Cohen, M. A., Dakin, C. L., Wren, A. M., Brynes, A. E., Low, M. J., Ghatei, M. A., et al. (2002) · Nature · doi:10.1038/nature00887 · Cited by 2,351 · see citing works

Inhibition of Food Intake in Obese Subjects by Peptide YY _3–36

Batterham, R. L., Cohen, M. A., Ellis, S. M., Le Roux, C. W., Withers, D. J., Frost, G. S., Ghatei, M. A., & Bloom, S. R. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030204 · Cited by 1,604 · see citing works

Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.

Flint, A., Raben, A., Astrup, A., & Holst, J. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci990 · Cited by 1,402 · see citing works

Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2

Gutzwiller, J., Drewe, J., Göke, B., Schmidt, H., Rohrer, B., Lareida, J., & Beglinger, C. (1999) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.1999.276.5.r1541 · Cited by 521 · see citing works

Pancreatic Polypeptide Reduces Appetite and Food Intake in Humans

Batterham, R. L., Le Roux, C. W., Cohen, M. A., Park, A. J., Ellis, S. M., Patterson, M., Frost, G. S., Ghatei, M. A., & Bloom, S. R. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030630 · Cited by 496 · see citing works

Oxyntomodulin Suppresses Appetite and Reduces Food Intake in Humans

Cohen, M. A., Ellis, S. M., le Roux, C. W., Batterham, R. L., Park, A., Patterson, M., Frost, G. S., Ghatei, M. A., & Bloom, S. R. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030421 · Cited by 473 · see citing works

Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men.

Näslund, E., Barkeling, B., King, N., Gutniak, M., Blundell, J., Holst, J., Rössner, S., & Hellström, P. (1999) · International Journal of Obesity · doi:10.1038/sj.ijo.0800818 · Cited by 468 · see citing works

Role of the Vagus Nerve in Mediating Proximal Nutrient-Induced Glucagon-Like Peptide-1 Secretion*

Rocca, A. S., & Brubaker, P. L. (1999) · Endocrinology · doi:10.1210/endo.140.4.6643 · Cited by 452 · see citing works

Trends in Intake of Energy and Macronutrients—United States, 1971-2000

(2004) · JAMA · doi:10.1001/jama.291.10.1193 · Cited by 321 · see citing works

Pramlintide as an Adjunct to Insulin Therapy Improves Long-Term Glycemic and Weight Control in Patients With Type 2 Diabetes

Hollander, P. A., Levy, P., Fineman, M. S., Maggs, D. G., Shen, L. Z., Strobel, S. A., Weyer, C., & Kolterman, O. G. (2003) · Diabetes Care · doi:10.2337/diacare.26.3.784 · Cited by 307 · see citing works

In vitro autoradiographic localization of amylin binding sites in rat brain

Sexton, P. M., Paxinos, G., Kenney, M. A., Wookey, P. J., & Beaumont, K. C. (1994) · Neuroscience · doi:10.1016/0306-4522(94)90388-3 · Cited by 277 · see citing works

An Amylin Receptor Is Revealed Following Co-Transfection of a Calcitonin Receptor with Receptor Activity Modifying Proteins-1 or -3

Muff, R., Bühlmann, N., Fischer, J. A., & Born, W. (1999) · Endocrinology · doi:10.1210/endo.140.6.6930 · Cited by 273 · see citing works

A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes

Whitehouse, F., Kruger, D. F., Fineman, M., Shen, L., Ruggles, J. A., Maggs, D. G., Weyer, C., & Kolterman, O. G. (2002) · Diabetes Care · doi:10.2337/diacare.25.4.724 · Cited by 264 · see citing works

Amylin decreases meal size in rats

Lutz, T. A. (1995) · Physiology & Behavior · doi:10.1016/0031-9384(95)02067-5 · Cited by 244 · see citing works

Effect of Exogenous Cholecystokinin (CCK)-8 on Food Intake and Plasma CCK, Leptin, and Insulin Concentrations in Older and Young Adults: Evidence for Increased CCK Activity as a Cause of the Anorexia of Aging

MacIntosh, C. G., Morley, J. E., Wishart, J. M., Morris, H. A., Jansen, J. B. �. �., Horowitz, M., & Chapman, I. M. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.12.8107 · Cited by 224 · see citing works

The anorectic effect of a chronic peripheral infusion of amylin is abolished in area postrema/nucleus of the solitary tract (AP/NTS) lesioned rats

Lutz, T., Mollet, A., Rushing, P. A., Riediger, T., & Scharrer, E. (2001) · International Journal of Obesity · doi:10.1038/sj.ijo.0801664 · Cited by 223 · see citing works

C-Terminal octapeptide of cholecystokinin decreases food intake in obese men

Pi‐Sunyer, X., Kissileff, H. R., Thornton, J., & Smith, G. P. (1982) · Physiology & Behavior · doi:10.1016/0031-9384(82)90230-x · Cited by 209 · see citing works

High affinity amylin binding sites in rat brain.

Beaumont, K. C., Kenney, M. A., Young, A. A., & RINK, T. J. (1993) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)13212-4 · Cited by 208 · see citing works

Amylin: A Novel Action in the Brain to Reduce Body Weight

Rushing, P. A., Hagan, M. M., Seeley, R. J., Lutz, T. A., & Woods, S. C. (2000) · Endocrinology · doi:10.1210/endo.141.2.7378 · Cited by 200 · see citing works

Effect of Pramlintide on Weight in Overweight and Obese Insulin‐Treated Type 2 Diabetes Patients

Hollander, P. A., Maggs, D. G., Ruggles, J. A., Fineman, M. S., Shen, L. Z., Kolterman, O., & Weyer, C. (2004) · Obesity Research · doi:10.1038/oby.2004.76 · Cited by 191 · see citing works

Amylin Replacement With Pramlintide as an Adjunct to Insulin Therapy in Type 1 and Type 2 Diabetes Mellitus: A Physiological Approach Toward Improved Metabolic Control

Weyer, C., Maggs, D., Young, A., & Kolterman, O. (2001) · Current Pharmaceutical Design · doi:10.2174/1381612013397357 · Cited by 175 · see citing works

Minireview: Gut Peptides Regulating Satiety

Druce, M. R., Small, C. J., & Bloom, S. R. (2004) · Endocrinology · doi:10.1210/en.2004-0089 · Cited by 174 · see citing works

Inhibition of Central Amylin Signaling Increases Food Intake and Body Adiposity in Rats

Rushing, P. A., Hagan, M. M., Seeley, R. J., Lutz, T. A., D’Alessio, D. A., Air, E. L., & Woods, S. C. (2001) · Endocrinology · doi:10.1210/endo.142.11.8593 · Cited by 173 · see citing works

Gastrointestinal correlates of the development of hunger in man

Sepple, C. P., & Read, N. W. (1989) · Appetite · doi:10.1016/0195-6663(89)90011-1 · Cited by 170 · see citing works

Physical state of meal affects gastric emptying, cholecystokinin release and satiety

Santangelo, A., PERACCHI, M., Conte, D., Fraquelli, M., & Porrini, M. (1998) · British Journal Of Nutrition · doi:10.1017/s0007114598001615 · Cited by 160 · see citing works

A Satiety Quotient: A Formulation to Assess the Satiating Effect of Food

GREEN, S., DELARGY, H., JOANES, D., & BLUNDELL, J. (1997) · Appetite · doi:10.1006/appe.1997.0096 · Cited by 160 · see citing works

Impact of Pramlintide on Glucose Fluctuations and Postprandial Glucose, Glucagon, and Triglyceride Excursions Among Patients With Type 1 Diabetes Intensively Treated With Insulin Pumps

Levetan, C. S., Want, L. L., Weyer, C., Strobel, S. A., Crean, J., Wang, Y., Maggs, D. G., Kolterman, O., Chandran, M., Mudaliar, S. R., et al. (2003) · Diabetes Care · doi:10.2337/diacare.26.1.1 · Cited by 156 · see citing works

Adjunctive Therapy with the Amylin Analogue Pramlintide Leads to a Combined Improvement in Glycemic and Weight Control in Insulin-Treated Subjects with Type 2 Diabetes

Ratner, R. E., Want, L. L., Fineman, M. S., Velte, M. J., Ruggles, J. A., Gottlieb, A., Weyer, C., & Kolterman, O. G. (2002) · Diabetes Technology & Therapeutics · doi:10.1089/15209150252924094 · Cited by 156 · see citing works

The Human Amylin Analog, Pramlintide, Reduces Postprandial Hyperglucagonemia in Patients with Type 2 Diabetes Mellitus

Fineman, M. S., Weyer, C., Maggs, D. G., Strobel, S. A., & Kolterman, O. (2002) · Hormone and Metabolic Research · doi:10.1055/s-2002-34790 · Cited by 147 · see citing works

Individual, but not simultaneous, glucagon and cholecystokinin infusions inhibit feeding in men

Geary, N., Kissileff, H. R., Pi-Sunyer, X., & Hinton, V. J. (1992) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.1992.262.6.r975 · Cited by 134 · see citing works

Gastrointestinal Satiety Signals III. Glucagon-like peptide 1, oxyntomodulin, peptide YY, and pancreatic polypeptide

Stanley, S. A., Wynne, K., & Bloom, S. R. (2004) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00536.2003 · Cited by 131 · see citing works

The Gut and Regulation of Body Weight

Wynne, K., Stanley, S. A., & Bloom, S. R. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0189 · Cited by 130 · see citing works

Effect of the menstrual cycle on energy and nutrient intake

Martini, M., Lampe, J. W., Slavin, J. L., & Kurzer, M. (1994) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/60.6.895 · Cited by 112 · see citing works

Effects of pramlintide, an amylin analogue, on gastric emptying in type 1 and 2 diabetes mellitus

VELLA, A., LEE, J. S., CAMILLERI, M., SZARKA, L. A., BURTON, D. D., ZINSMEISTER, A. R., RIZZA, R. A., & KLEIN, P. D. (2002) · Neurogastroenterology & Motility · doi:10.1046/j.1365-2982.2002.00311.x · Cited by 112 · see citing works

Subdiaphragmatic vagotomy does not influence the anorectic effect of amylin

Lutz, T. A., Prete, E. D., & Scharrer, E. (1995) · Peptides · doi:10.1016/0196-9781(94)00203-i · Cited by 103 · see citing works

The Pharmacology of Human Appetite Expression

Halford, J. C. G., Cooper, G. D., & Dovey, T. M. (2004) · Current Drug Targets · doi:10.2174/1389450043490541 · Cited by 97 · see citing works

Amylin receptor blockade stimulates food intake in rats

Reidelberger, R. D., Haver, A. C., Arnelo, U., Smith, D. D., Schaffert, C. S., & Permert, J. (2004) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00213.2004 · Cited by 90 · see citing works

Amylinʼs physiology and its role in diabetes

Young, A. A. (1997) · Current Opinion in Endocrinology & Diabetes · doi:10.1097/00060793-199708000-00006 · Cited by 87 · see citing works

Effect of low glycogen on carbohydrate and energy metabolism in human muscle during exercise

SPENCER, M. K., Yan, Z., & Katz, A. L. (1992) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.1992.262.4.c975 · Cited by 84 · see citing works

Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 diabetes: a dose‐timing study

Maggs, D. G., Fineman, M. S., Kornstein, J., Burrell, T., Schwartz, S. L., Wang, Y., Ruggles, J. A., Kolterman, O., & Weyer, C. (2004) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.419 · Cited by 77 · see citing works

Unresolved Challenges with Insulin Therapy in Type 1 and Type 2 Diabetes: Potential Benefit of Replacing Amylin, a Second β -Cell Hormone

Edelman, S. V., & Weyer, C. (2002) · Diabetes Technology & Therapeutics · doi:10.1089/15209150260007390 · Cited by 74 · see citing works

Central regulators of food intake.

Druce, M. R., & Bloom, S. R. (2003) · PubMed · doi:10.1097/01.mco.0000078996.96795.4a · Cited by 41 · see citing works

Effects of cholecystokinin on appetite and pyloric motility during physiological hyperglycemia

Rayner, C. K., Park, H. S., Doran, S., Chapman, I. M., & Horowitz, M. (2000) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.2000.278.1.g98 · Cited by 38 · see citing works

Effects of Somatostatin on Human Satiety

Lieverse, R. J., Jansen, J. B. �. �., Masclee, A., & Lamers, C. B. H. W. (2008) · Neuroendocrinology · doi:10.1159/000126831 · Cited by 37 · see citing works

Amylin and Insulin Interact to Reduce Food Intake in Rats

Rushing, P., Lutz, T., Seeley, R., & Woods, S. (2000) · Hormone and Metabolic Research · doi:10.1055/s-2007-978590

Evolution of the human life cycle

Bogin, B., & Smith, B. H. (1996) · American Journal of Human Biology · doi:10.1002/(sici)1520-6300(1996)8:6

A within-trial cost-effectiveness analysis of primary care referral to a commercial provider for weight loss treatment, relative to standard care—an international randomised controlled trial

Fuller, N. R., Colagiuri, S., SCHOFIELD, D. J., Olson, A. D., Shrestha, R. N., Holzapfel, C., Wolfenstetter, S. B., Holle, R., Ahern, A. L., Hauner, H., et al. (2012) · International Journal of Obesity · doi:10.1038/ijo.2012.139 · Cited by 2,125 · see citing works

Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline

Apovian, C. M., Aronne, L. J., Bessesen, D. H., McDonnell, M. E., Murad, M. H., Pagotto, U., Ryan, D. H., & Still, C. D. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3415 · Cited by 1,347 · see citing works

The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

Holt, R. I. G., DeVries, J. H., Hess-Fischl, A., Hirsch, I. B., Kirkman, M. S., Klupa, T., Ludwig, B., Nørgaard, K., Pettus, J., Renard, E., et al. (2021) · Diabetes Care · doi:10.2337/dci21-0043 · Cited by 699 · see citing works

Amylin: Pharmacology, Physiology, and Clinical Potential

Hay, D. L., Chen, S., Lutz, T. A., Parkes, D. G., & Roth, J. D. (2015) · Pharmacological Reviews · doi:10.1124/pr.115.010629 · Cited by 400 · see citing works

The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

Holt, R. I. G., DeVries, J. H., Fischl, A. H., Hirsch, I. B., Kirkman, M. S., Klupa, T., Ludwig, B., Nørgaard, K., Pettus, J., Renard, É., et al. (2021) · Diabetologia · doi:10.1007/s00125-021-05568-3 · Cited by 427 · see citing works

Enhanced Weight Loss With Pramlintide/Metreleptin: An Integrated Neurohormonal Approach to Obesity Pharmacotherapy

Ravussin, É., Smith, S. R., Mitchell, J. A., Shringarpure, R., Shan, K., Maier, H., Koda, J. E., & Weyer, C. (2009) · Obesity · doi:10.1038/oby.2009.184 · Cited by 335 · see citing works

New frontiers in the treatment of type 1 diabetes

Warshauer, J. T., Bluestone, J. A., & Anderson, M. S. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2019.11.017 · Cited by 259 · see citing works

Dual-process action of exercise on appetite control: increase in orexigenic drive but improvement in meal-induced satiety

King, N. A., Caudwell, P. P., Hopkins, M., Stubbs, J. R., Naslund, E., & Blundell, J. E. (2009) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.2009.27706 · Cited by 226 · see citing works

The obesity pipeline: current strategies in the development of anti-obesity drugs

Cooke, D., & Bloom, S. R. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2136 · Cited by 212 · see citing works

The role of gut hormones in the regulation of body weight and energy homeostasis

Karra, E., & Batterham, R. L. (2009) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2009.06.010 · Cited by 210 · see citing works

Drug therapy in obesity: a review of current and emerging treatments

Williams, D. M., Nawaz, A., & Evans, M. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00816-y · Cited by 195 · see citing works

Pharmacotherapy of type 2 diabetes: An update

Upadhyay, J., Pοlyzos, S. A., Perakakis, N., Thakkar, B., Paschou, S. Α., Katsiki, N., UNDERWOOD, P. C., Park, K., Seufert, J., Kang, E. S., et al. (2017) · Metabolism · doi:10.1016/j.metabol.2017.08.010 · Cited by 190 · see citing works

Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes

Horowitz, M., Flint, A., Jones, K. L., Hindsberger, C., Rasmussen, M. F., Kapitza, C., Doran, S., Jax, T., Zdravkovic, M., & Chapman, I. M. (2012) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2012.02.016 · Cited by 179 · see citing works

Progressive Reduction in Body Weight after Treatment with the Amylin Analog Pramlintide in Obese Subjects: A Phase 2, Randomized, Placebo-Controlled, Dose-Escalation Study

Aronne, L., Fujioka, K., Aroda, V., Chen, K., Halseth, A., Kesty, N. C., Burns, C., Lush, C. W., & Weyer, C. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-2003 · Cited by 178 · see citing works

CNS regulation of appetite

Harrold, J. A., Dovey, T. M., Blundell, J. E., & Halford, J. C. G. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.01.007 · Cited by 177 · see citing works

The role of amylin in the control of energy homeostasis

Lutz, T. A. (2010) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00703.2009 · Cited by 176 · see citing works

Amylinergic control of food intake

Lutz, T. A. (2006) · Physiology & Behavior · doi:10.1016/j.physbeh.2006.04.001 · Cited by 175 · see citing works

Sustained Weight Loss Following 12-Month Pramlintide Treatment as an Adjunct to Lifestyle Intervention in Obesity

Smith, S. R., Aronne, L. J., Burns, C. M., Kesty, N. C., Halseth, A. E., & Weyer, C. (2008) · Diabetes Care · doi:10.2337/dc08-0029 · Cited by 172 · see citing works

A double-blind, placebo-controlled trial assessing pramlintide treatment in the setting of intensive insulin therapy in type 1 diabetes

Edelman, S., Garg, S., Frias, J., Maggs, D., Wang, Y., Zhang, B., Strobel, S., Lutz, K., & Kolterman, O. (2006) · Diabetes Care · doi:10.2337/dc06-0042 · Cited by 166 · see citing works

Issues in Measuring and Interpreting Human Appetite (Satiety/Satiation) and Its Contribution to Obesity

Gibbons, C., Hopkins, M., Beaulieu, K., Oustric, P., & Blundell, J. E. (2019) · Current Obesity Reports · doi:10.1007/s13679-019-00340-6 · Cited by 172 · see citing works

Pharmacological management of appetite expression in obesity

Halford, J. C. G., Boyland, E. J., Blundell, J. E., Kirkham, T. C., & Harrold, J. A. (2010) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.19 · Cited by 142 · see citing works

Control of energy homeostasis by amylin

Lutz, T. A. (2011) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-011-0905-1 · Cited by 136 · see citing works

Pramlintide treatment reduces 24-h caloric intake and meal sizes and improves control of eating in obese subjects: a 6-wk translational research study

Smith, S. R., Blundell, J. E., Burns, C. M., Ellero, C., Schroeder, B. E., Kesty, N. C., Chen, K. S., Halseth, A. E., Lush, C. W., & Weyer, C. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00217.2007 · Cited by 131 · see citing works

Can We Really Close the Loop and How Soon? Accelerating the Availability of an Artificial Pancreas: A Roadmap to Better Diabetes Outcomes

Kowalski, A. J. (2009) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2009.0031 · Cited by 127 · see citing works

Alterations in Gut Hormones After Laparoscopic Sleeve Gastrectomy

Dimitriadis, E., Daskalakis, M., Kampa, M., Peppe, A., Papadakis, J. A., & Melissas, J. (2012) · Annals of Surgery · doi:10.1097/sla.0b013e31826e1846 · Cited by 122 · see citing works

New Drugs for Type 2 Diabetes Mellitus

Krentz, A. J., Patel, M., & Bailey, C. J. (2008) · Drugs · doi:10.2165/00003495-200868150-00005 · Cited by 121 · see citing works

GLP-1 and Amylin in the Treatment of Obesity

Jorsal, T., Rungby, J., Knop, F. K., & Vilsbøll, T. (2015) · Current Diabetes Reports · doi:10.1007/s11892-015-0693-3 · Cited by 124 · see citing works

Amylin Modulates the Mesolimbic Dopamine System to Control Energy Balance

Mietlicki‐Baase, E. G., Reiner, D. J., Cone, J. J., Olivos, D. R., McGrath, L. E., Zimmer, D. J., Roitman, M. F., & Hayes, M. R. (2014) · Neuropsychopharmacology · doi:10.1038/npp.2014.180 · Cited by 116 · see citing works

Pramlintide Improved Glycemic Control and Reduced Weight in Patients With Type 2 Diabetes Using Basal Insulin

Riddle, M., Frias, J., Zhang, B., Maier, H., Brown, C., Lutz, K., & Kolterman, O. (2007) · Diabetes Care · doi:10.2337/dc07-0589 · Cited by 116 · see citing works

Effects of dietary polyphenols on neuroregulatory factors and pathways that mediate food intake and energy regulation in obesity

Panickar, K. S. (2012) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201200431 · Cited by 115 · see citing works

Insulin-associated weight gain in obese type 2 diabetes mellitus patients: What can be done?

Brown, A., Guess, N., Dornhorst, A., Taheri, S., & Frost, G. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13009 · Cited by 113 · see citing works

Davalintide (AC2307), a novel amylin-mimetic peptide: enhanced pharmacological properties over native amylin to reduce food intake and body weight

Mack, C. M., Soares, C. J., Wilson, J., Athanacio, J., Turek, V. F., Trevaskis, J. L., Roth, J. D., Smith, P. A., Gedulin, B. R., Jodka, C. M., et al. (2009) · International Journal of Obesity · doi:10.1038/ijo.2009.238 · Cited by 111 · see citing works

Emerging Therapies Mimicking the Effects of Amylin and Glucagon-Like Peptide 1

Riddle, M. C., & Drucker, D. J. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-1267 · Cited by 108 · see citing works

Pharmacological actions of the peptide hormone amylin in the long-term regulation of food intake, food preference, and body weight.

Mack, C. M., Wilson, J., Athanacio, J., Reynolds, J. M., Laugero, K., Guss, S., Vu, C., Roth, J., & Parkes, D. (2007) · American Journal of Physiology. Regulatory Integrative and Comparative Physiology · doi:10.1152/ajpregu.00297.2007 · Cited by 115 · see citing works

Pramlintide and the treatment of diabetes: a review of the data since its introduction

Younk, L. M., Mikeladze, M., & Davis, S. N. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.581663 · Cited by 99 · see citing works

Metabolic stress, <scp>IAPP</scp> and islet amyloid

Montane, J., Klimek‐Abercrombie, A., Potter, K. J., Westwell‐Roper, C., & Bruce Verchere, C. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01657.x · Cited by 98 · see citing works

Non-insulin drugs to treat hyperglycaemia in type 1 diabetes mellitus

Frandsen, C. S., Dejgaard, T. F., & Madsbad, S. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)00039-5 · Cited by 95 · see citing works

Efficacy and risk profile of anti-diabetic therapies: Conventional vs traditional drugs—A mechanistic revisit to understand their mode of action

Gupta, P., Bala, M., Gupta, S. K., Dua, A., Dabur, R., Injeti, E. R., & Mittal, A. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.09.029 · Cited by 90 · see citing works

Pramlintide, the synthetic analogue of amylin: physiology, pathophysiology, and effects on glycemic control, body weight, and selected biomarkers of vascular risk

Hoogwerf, B. J. (2008) · Vascular Health and Risk Management · doi:10.2147/vhrm.s1978 · Cited by 87 · see citing works

No Sex Difference in Body Fat in Response to Supervised and Measured Exercise

CAUDWELL, P., GIBBONS, C., HOPKINS, M., KING, N., FINLAYSON, G., & BLUNDELL, J. (2013) · Medicine &amp; Science in Sports &amp; Exercise · doi:10.1249/mss.0b013e31826ced79 · Cited by 86 · see citing works

Role of Amylin in Type 1 and Type 2 Diabetes

Hieronymus, L. B., & Griffin, S. (2015) · The Science of Diabetes Self-Management and Care · doi:10.1177/0145721715607642 · Cited by 86 · see citing works

Diabetes mellitus: new challenges and innovative therapies

Sena, C., Bento, C. F., Pereira, P., & Seiça, R. (2010) · The EPMA Journal · doi:10.1007/s13167-010-0010-9 · Cited by 83 · see citing works

Anti-Diabetes and Anti-Obesity Medications: Effects on Weight in People With Diabetes

Hollander, P. A. (2007) · Diabetes Spectrum · doi:10.2337/diaspect.20.3.159 · Cited by 81 · see citing works

Current and Future Drug Targets in Weight Management

Witkamp, R. F. (2010) · Pharmaceutical Research · doi:10.1007/s11095-010-0341-1 · Cited by 78 · see citing works

Combination Therapy with Amylin and Peptide YY[3–36] in Obese Rodents: Anorexigenic Synergy and Weight Loss Additivity

Roth, J. D., Coffey, T. S., Jodka, C. M., Maier, H., Athanacio, J., Mack, C. M., Weyer, C., & Parkes, D. G. (2007) · Endocrinology · doi:10.1210/en.2007-0898 · Cited by 78 · see citing works

Metabolic Phenotyping Guidelines: studying eating behaviour in humans

Gibbons, C., Finlayson, G., Dalton, M., Caudwell, P., & Blundell, J. E. (2014) · Journal of Endocrinology · doi:10.1530/joe-14-0020 · Cited by 74 · see citing works

Effects of palatability and learned satiety on energy density influences on breakfast intake in humans

Yeomans, M. R., WEINBERG, L., & JAMES, S. (2005) · Physiology & Behavior · doi:10.1016/j.physbeh.2005.08.019 · Cited by 76 · see citing works

The effect of pramlintide acetate on glycemic control and weight in patients with type 2 diabetes mellitus and in obese patients without diabetes: a systematic review and meta‐analysis

Singh‐Franco, D., Pérez, A., & Harrington, C. A. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01337.x · Cited by 75 · see citing works

Pramlintide acetate injection for the treatment of type 1 and type 2 diabetes mellitus

Singh‐Franco, D., Robles, G. I., & Gazze, D. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.04.005 · Cited by 75 · see citing works

New approaches to the pharmacological treatment of obesity: Can they break through the efficacy barrier?

Kennett, G. A., & Clifton, P. G. (2010) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2010.07.020 · Cited by 75 · see citing works

Molecular Structure, Membrane Interactions, and Toxicity of the Islet Amyloid Polypeptide in Type 2 Diabetes Mellitus

Caillon, L., Hoffmann, A. R. F., Botz, A., & Khemtémourian, L. (2015) · Journal of Diabetes Research · doi:10.1155/2016/5639875 · Cited by 73 · see citing works

Mediators of Amylin Action in Metabolic Control

Boyle, C. N., Zheng, Y., & Lutz, T. A. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11082207 · Cited by 67 · see citing works

Pramlintide in the Treatment of Diabetes Mellitus

Edelman, S. V., Maier, H., & Wilhelm, K. (2008) · BioDrugs · doi:10.2165/0063030-200822060-00004 · Cited by 68 · see citing works

Randomized comparison of pramlintide or mealtime insulin added to basal insulin treatment for patients with type 2 diabetes

Riddle, M., Pencek, R., Charenkavanich, S., Lutz, K., Wilhelm, K., & Porter, L. (2009) · Diabetes Care · doi:10.2337/dc09-0395 · Cited by 66 · see citing works

Amylin activates distributed CNS nuclei to control energy balance

Mietlicki‐Baase, E. G., & Hayes, M. R. (2014) · Physiology & Behavior · doi:10.1016/j.physbeh.2014.01.013 · Cited by 66 · see citing works

Low‐dose Pramlintide Reduced Food Intake and Meal Duration in Healthy, Normal‐Weight Subjects

Chapman, I. M., Parker, B. A., Doran, S., Feinle‐Bisset, C., Wishart, J. M., Lush, C. W., Chen, K. S., LaCerte, C., Burns, C. M., McKay, R., et al. (2007) · Obesity · doi:10.1038/oby.2007.626 · Cited by 64 · see citing works

Pramlintide in the management of insulin-using patients with type 2 and type 1 diabetes

Pullman, J. R., Darsow, T., & Frías, J. P. (2006) · Vascular Health and Risk Management · doi:10.2147/vhrm.2006.2.3.203 · Cited by 64 · see citing works

The β Cell in Diabetes: Integrating Biomarkers With Functional Measures

Kahn, S. E., Chen, Y., Esser, N., Taylor, A. J., van Raalte, D. H., Zraika, S., & Verchere, C. B. (2021) · Endocrine Reviews · doi:10.1210/endrev/bnab021 · Cited by 69 · see citing works

Amylin-mediated control of glycemia, energy balance, and cognition

Mietlicki‐Baase, E. G. (2016) · Physiology & Behavior · doi:10.1016/j.physbeh.2016.02.034 · Cited by 62 · see citing works

Prevention and Treatment of Type 2 Diabetes in Youth

Libman, I. M., & Arslanian, S. A. (2006) · Hormone Research in Paediatrics · doi:10.1159/000095981 · Cited by 62 · see citing works

The interaction of amylin with other hormones in the control of eating

Lutz, T. A. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01670.x · Cited by 59 · see citing works

Drugs on the horizon for diabesity

Bailey, C. J. (2005) · Current Diabetes Reports · doi:10.1007/s11892-005-0093-1 · Cited by 58 · see citing works

Creating the amylin story

Lutz, T. A. (2022) · Appetite · doi:10.1016/j.appet.2022.105965 · Cited by 59 · see citing works

Mono and dual agonists of the amylin, calcitonin, and CGRP receptors and their potential in metabolic diseases

Sonne, N., Karsdal, M. A., & Henriksen, K. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101109 · Cited by 57 · see citing works

Adjunct therapy for type 1 diabetes mellitus

Lebovitz, H. E. (2010) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.49 · Cited by 57 · see citing works

Efficacy and safety of pramlintide injection adjunct to insulin therapy in patients with type 1 diabetes mellitus: a systematic review and meta-analysis

Qiao, Y.-C., Ling, W., Pan, Y.-H., Chen, Y.-L., Zhou, D., Huang, Y.-M., Zhang, X.-X., & Zhao, H.-L. (2017) · Oncotarget · doi:10.18632/oncotarget.16008 · Cited by 54 · see citing works

Control of food intake and energy expenditure by amylin—therapeutic implications

Lutz, T. A. (2009) · International Journal of Obesity · doi:10.1038/ijo.2009.13 · Cited by 53 · see citing works

Weak Satiety Responsiveness Is a Reliable Trait Associated with Hedonic Risk Factors for Overeating among Women

Dalton, M., Hollingworth, S., Blundell, J. E., & Finlayson, G. (2015) · Nutrients · doi:10.3390/nu7095345 · Cited by 52 · see citing works

Glucoregulatory effects and prolonged duration of action of davalintide: a novel amylinomimetic peptide

Mack, C. M., Smith, P. A., Athanacio, J., Xu, K., Wilson, J., Reynolds, J. M., Jodka, C. M., Lu, M. G. W., & Parkes, D. G. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01465.x · Cited by 50 · see citing works

Effect of Adjunctive Pramlintide Treatment on Treatment Satisfaction in Patients With Type 1 Diabetes

Marrero, D. G., Crean, J., Zhang, B., Kellmeyer, T., Gloster, M., Herrmann, K., Rubin, R. R., Fineberg, N. S., & Kolterman, O. (2007) · Diabetes Care · doi:10.2337/dc06-1026 · Cited by 49 · see citing works

Effects of Amylin on Eating and Adiposity

Lutz, T. A. (2011) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-24716-3_10 · Cited by 48 · see citing works

The influence of physical activity on appetite control: an experimental system to understand the relationship between exercise-induced energy expenditure and energy intake

Caudwell, P., Gibbons, C., Hopkins, M., Näslund, E. B., King, N. A., Finlayson, G., & Blundell, J. E. (2011) · Proceedings of The Nutrition Society · doi:10.1017/s0029665110004751 · Cited by 46 · see citing works

A novel oral form of salmon calcitonin improves glucose homeostasis and reduces body weight in diet‐induced obese rats

Feigh, M., Henriksen, K., Andreassen, K. V., Hansen, C., Henriksen, J. E., Beck‐Nielsen, H., Christiansen, C., & Karsdal, M. A. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01425.x · Cited by 45 · see citing works

Amylin and the regulation of appetite and adiposity

Roth, J. D. (2013) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e32835b896f · Cited by 45 · see citing works

Neuroendocrine Control of Food Intake

Butler, A. A., Trevaskis, J. L., & Morrison, C. D. (2007) · Springer eBooks · doi:10.1007/978-0-387-32164-6_1 · Cited by 44 · see citing works

It Takes Two to Tango: Combined Amylin/Leptin Agonism as a Potential Approach to Obesity Drug Development

Chan, J. L., Roth, J. D., & Weyer, C. (2009) · Journal of Investigative Medicine · doi:10.2310/jim.0b013e3181b91911 · Cited by 44 · see citing works

Antiobesity effects of the β-cell hormone amylin in combination with phentermine or sibutramine in diet-induced obese rats

Roth, J. D., Trevaskis, J. L., Wilson, J., Lei, C., Athanacio, J., Mack, C. M., Kesty, N. C., Coffey, T. S., Weyer, C., & Parkes, D. G. (2008) · International Journal of Obesity · doi:10.1038/ijo.2008.91 · Cited by 43 · see citing works

Endogenous VMH amylin signaling is required for full leptin signaling and protection from diet-induced obesity

Dunn-Meynell, A. A., Foll, C. L., Johnson, M. D., Lutz, T. A., Hayes, M. R., & Levin, B. E. (2015) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00462.2015 · Cited by 43 · see citing works

Amylin

Hay, D. L. (2017) · Headache The Journal of Head and Face Pain · doi:10.1111/head.13077 · Cited by 42 · see citing works

New Targets for Drug Treatment of Obesity

Valsamakis, G., Konstantakou, P., & Mastorakos, G. P. (2017) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010716-104735 · Cited by 41 · see citing works

Pharmacological management of obesity an endocrine society clinical practice guideline

Apovian, C. M., Aronne, L. J., Bessesen, D. H., McDonnell, M. E., Murad, M. H., Pagotto, U., Ryan, D. H., & Still, C. D. (2015) · Reproductive Endocrinology · doi:10.18370/2309-4117.2015.23.59-63 · Cited by 42 · see citing works

Mechanisms of current therapies for diabetes mellitus type 2

Thulé, P. M. (2012) · AJP Advances in Physiology Education · doi:10.1152/advan.00094.2012 · Cited by 40 · see citing works

Weight Considerations in Pharmacotherapy for Type 2 Diabetes

Cheng, V., & Kashyap, S. R. (2010) · Journal of Obesity · doi:10.1155/2011/984245 · Cited by 39 · see citing works

Upper gastrointestinal function and glycemic control in diabetes mellitus

Chaikomin, R. (2006) · World Journal of Gastroenterology · doi:10.3748/wjg.v12.i35.5611 · Cited by 39 · see citing works

Pramlintide Lowered Glucose Excursions and Was Well-Tolerated in Adolescents with Type 1 Diabetes: Results from a Randomized, Single-Blind, Placebo-Controlled, Crossover Study

Chase, H. P., Lutz, K., Pencek, R., Zhang, B., & Porter, L. (2009) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2009.03.012 · Cited by 39 · see citing works

Pramlintide as An Adjunct to Insulin in Patients with Type 2 Diabetes in A Clinical Practice Setting Reduced A1C, Postprandial Glucose Excursions, And Weight

Karl, D. M., Philis‐Tsimikas, A., Darsow, T., Lorenzi, G. M., Kellmeyer, T., Lutz, K., Wang, Y., & Frías, J. P. (2007) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2006.0013 · Cited by 38 · see citing works

Human Amylin: From Pathology to Physiology and Pharmacology

Ling, W., Huang, Y., Qiao, Y.-C., Zhang, X., & Zhao, H. (2019) · Current Protein and Peptide Science · doi:10.2174/1389203720666190328111833 · Cited by 37 · see citing works

Adiposopathy: treating pathogenic adipose tissue to reduce cardiovascular disease risk

Bays, H., Rodbard, H. W., Schorr, A. B., & González-Campoy, J. M. (2007) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-007-0021-6 · Cited by 36 · see citing works

Amylin: emergent therapeutic opportunities in overweight, obesity and diabetes mellitus

Walker, C. S., Aitken, J. F., Amarsingh, G. V., Zhang, S., & Cooper, G. J. S. (2025) · Nature Reviews Endocrinology · doi:10.1038/s41574-025-01125-9 · Cited by 37 · see citing works

Cost effectiveness of duloxetine in the treatment of diabetic peripheral neuropathic pain in the UK

Beard, S. M., McCrink, L., Le, T. K., Garcia-Cebrian, A., Monz, B. U., & Malik, R. A. (2007) · Current Medical Research and Opinion · doi:10.1185/030079908x253852 · Cited by 34 · see citing works

Glucose homeostasis and the gastrointestinal tract: insights into the treatment of diabetes

Maggs, D. G., Macdonald, I. A., & Nauck, M. A. (2007) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2007.00737.x · Cited by 34 · see citing works

Novel therapies for the management of type 2 diabetes mellitus: Part 1. Pramlintide and bromocriptine‐ QR (2型糖尿病治疗新药：第1部分.普兰林肽与溴隐亭‐QR)

Grunberger, G. (2013) · Journal of Diabetes · doi:10.1111/1753-0407.12034 · Cited by 32 · see citing works

Effect of pramlintide as an adjunct to basal insulin on markers of cardiovascular risk in patients with type 2 diabetes

Wysham, C., Lush, C. W., Zhang, B., Maier, H., & Wilhelm, K. (2007) · Current Medical Research and Opinion · doi:10.1185/030079908x253537 · Cited by 32 · see citing works

Role of gastrointestinal hormones in feeding behavior and obesity treatment

Kairupan, T. S., Amitani, H., Cheng, K., Runtuwene, J., Asakawa, A., & Inui, A. (2015) · Journal of Gastroenterology · doi:10.1007/s00535-015-1118-4 · Cited by 29 · see citing works

Management of type 2 diabetes: the role of incretin mimetics

Stonehouse, A. H., Holcombe, J. H., & Kendall, D. M. (2006) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.7.15.2095 · Cited by 29 · see citing works

Effects of prior or concurrent food restriction on amylin-induced changes in body weight and body composition in high-fat-fed female rats

Roth, J. D., Hughes, H., Coffey, T. S., Maier, H., Trevaskis, J. L., & Anderson, C. M. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00395.2007 · Cited by 28 · see citing works

National survey of pediatric fever management practices among emergency department nurses.

Thomas, V., Riegel, B. J., Andrea, J., Murray, P., Gerhart, A. E., & Gocka, I. (1994) · PubMed · Cited by 27 · see citing works

Actions of feeding-related peptides on the mesolimbic dopamine system in regulation of natural and drug rewards

Dunigan, A. I., & Roseberry, A. G. (2022) · Addiction Neuroscience · doi:10.1016/j.addicn.2022.100011 · Cited by 28 · see citing works

A systematic review of the use of the Satiety Quotient

Fillon, A., Beaulieu, K., Mathieu, M.-E., Tremblay, A., Boirie‌, Y., Drapeau, V., & Thivel, D. (2020) · British Journal Of Nutrition · doi:10.1017/s0007114520002457 · Cited by 25 · see citing works

Effects of Sodium-Glucose Cotransporter Inhibitor/Glucagon-Like Peptide-1 Receptor Agonist Add-On to Insulin Therapy on Glucose Homeostasis and Body Weight in Patients With Type 1 Diabetes: A Network Meta-Analysis

Kim, Y. J., Hwang, S. D., & Lim, S. K. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00553 · Cited by 24 · see citing works

Low‐dose Pramlintide Reduced Food Intake and Meal Duration in Healthy, Normal‐Weight Subjects

Chapman, I. M., Parker, B. A., Doran, S., Feinle‐Bisset, C., Wishart, J. M., Lush, C. W., Chen, K. S., LaCerte, C., Burns, C. M., McKay, R., et al. (2007) · Obesity · doi:10.1038/oby.2007.626 · Cited by 64 · see citing works

The Role of Pramlintide for Weight Loss

Dunican, K. C., Adams, N. M., & Desilets, A. R. (2010) · Annals of Pharmacotherapy · doi:10.1345/aph.1m210 · Cited by 50 · see citing works

Effects of pramlintide on energy intake and food preference in rats given a choice diet

Kern, K. A., DiBrog, A. M., Przybysz, J. T., & Mietlicki‐Baase, E. G. (2021) · Physiology & Behavior · doi:10.1016/j.physbeh.2021.113541 · Cited by 7 · see citing works

Pramlintide as an Adjunct to Insulin Therapy Improves Long-Term Glycemic and Weight Control in Patients With Type 2 Diabetes

Hollander, P. A., Levy, P., Fineman, M. S., Maggs, D. G., Shen, L. Z., Strobel, S. A., Weyer, C., & Kolterman, O. G. (2003) · Diabetes Care · doi:10.2337/diacare.26.3.784 · Cited by 307 · see citing works

Progressive Reduction in Body Weight after Treatment with the Amylin Analog Pramlintide in Obese Subjects: A Phase 2, Randomized, Placebo-Controlled, Dose-Escalation Study

Aronne, L., Fujioka, K., Aroda, V., Chen, K., Halseth, A., Kesty, N. C., Burns, C., Lush, C. W., & Weyer, C. (2007) · The Journal of Clinical Endocrinology &amp; Metabolism · doi:10.1210/jc.2006-2003 · Cited by 178 · see citing works